Immunovant earnings were -$538.2M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest IMVT earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$153.2M, up 3.6% from last quarter. For the last reported fiscal year 2026 ending Mar 31, 2026, IMVT reported annual earnings of -$505.6M, with 22.2% growth. The next IMVT earnings date is Nov 9, 2026.
On IMVT's earnings call on Aug 6, 2026, Immunovant (NASDAQ: IMVT) reported Q2 2026 earnings per share (EPS) of -$0.75, up 5.63% year over year. Total IMVT earnings for the quarter were -$153.22 million. In the same quarter last year, Immunovant's earnings per share (EPS) was -$0.71.
The next IMVT earnings call is Nov 9, 2026. Add IMVT to your watchlist to be reminded of Immunovant's next earnings date.
Is Immunovant profitable or losing money?
As of the last Immunovant earnings report, Immunovant is currently losing money. Immunovant's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$538.22 million, a 20.32% increase year over year.
What was IMVT's earnings growth in the past year?
As of Immunovant's earnings date in Aug 6, 2026, Immunovant's earnings has grown year over year. IMVT earnings in the past year totalled -$538.22 million.
What are Immunovant's earnings expectations?
The current EPS estimate for Immunovant's earnings report in Nov 9, 2026 is -$0.73.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.